查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464907

Duchenne氏肌肉失養症治療藥物市場：按藥物類型、給藥方法和最終用途分類 - 全球預測 2024-2030

Duchenne Muscular Dystrophy Drugs Market by Drug Type (Casimersen, Deflazacort, Delandistrogene Moxeparvovec), Administration Method (Oral, Parental), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Duchenne氏肌肉失養症治療藥物市場規模預計2023年為15.7億美元，預計2024年將達17億美元，2030年將達28億美元，複合年成長率為8.61%。

Duchenne氏肌肉失養症(DMD) 治療市場專注於專門用於治療 DMD 的藥品的銷售、開拓和生產，DMD 是一種以進行性肌肉退化和肌無力為特徵的遺傳性疾病。基因研究的進步和對 DMD 基因基礎了解的突破正在帶來更有針對性和更有效的治療方法，有助於市場擴張。全球醫療保健支出的增加正在改善 DMD 治療的可近性並有助於市場擴張。政府和非營利組織的資金和舉措正在支持研究和開發工作，並促進將 DMD 治療引入市場。對藥物核准和市場引入的嚴格監管要求可能會延遲獲得創新療法的機會，並且是市場領域的一個挑戰。此外，基因編輯技術的進步，如CRISPR/Cas9和其他基因編輯工具，為Duchenne氏肌肉失養症的治療提供了可能性。根據個人基因譜量身定做的個人化醫療方法的開發有可能提高療效並最大限度地減少副作用，從而為市場成長創造機會。

主要市場統計
基準年[2023] 15.7億美元
預測年份 [2024] 17億美元
預測年份 [2030] 28億美元
複合年成長率（%） 8.61%

藥物類型：卡西默森擴大被偏好作為Duchenne氏肌肉失養症的標靶治療

Casimersen 被核准用於治療已確診的外顯子 45 跳躍突變的 DMD 患者。這種基於需求的卡迪默森偏好對於具有某些遺傳傾向的患者至關重要，並提供了標靶治療選擇。無論特定的基因突變如何，地夫可特都能有效減緩 DMD 的進展並提高廣大患者的肌肉力量。 Derandystrogen moxeparvovec (Roctavian) 基因療法的目標患者是那些將從直接糾正導致 DMD 的基因缺陷的方法中受益的患者。 Eteplirsen (exondis51) 適用於因外顯子 51 跳躍而確認 DMD 基因突變的 DMD 患者。 Golodirsen 滿足小眾病患小組的需求，並針對外顯子 53 跳躍的特定基因突變提供標靶基因治療。 Viltolarsen 被核准用於治療外顯子 53 跳躍的 DMD 患者，透過針對特定基因突變為受影響的患者提供精準醫療方法。

最終用途：門診 DMD 治療的採用率增加

門診中心，也稱為流動護理中心，為不需要住院的患者提供醫療服務。門診中心因其便利性和成本效益而日益成為 DMD 等慢性疾病的常規檢查、診斷和治療的首選。居家照護設施是一個快速發展的領域，可滿足患者在自己家中接受醫療保健服務的願望，包括 DMD 藥物治療。居家照護在患者舒適的家中提供持續、個人化的 DMD 藥物治療和管理。

區域洞察

美國和加拿大是參與Duchenne氏肌肉失養症(DMD) 治療藥物開發的主要企業的重要區域。美洲地區的特點是消費者意識高、研發投入高、政府政策優惠。美國在突破性治療方法的開發中佔據關鍵地位，並已為創新的 DMD治療方法申請了多項專利。加拿大展現了強而有力的政府支持和官民合作關係來促進市場成長。歐盟 (EU) 國家一直處於 DMD 藥物開發監管支持的最前沿，並採取了多項舉措來支持研究和獲得治療。歐洲、中東和非洲地區的專利活動非常活躍，多個國家都對發現做出了貢獻。中東地區市場規模雖小，但投資不斷加大，認可度不斷提高。非洲在醫療保健基礎設施和治療取得方面面臨挑戰，並透過國際夥伴關係和投資提供成長潛力。亞太地區，特別是中國、日本和印度，DMD 治療市場正在顯著成長。亞太地區國家的市場成長歸功於意識的提高、政府措施和醫療基礎設施的改善。亞太地區國家的研究和投資十分活躍，其中日本在創新治療方法和專利申請方面處於領先地位。中國和印度正在迅速推進研究並提供具有成本效益的治療方法，顯著影響市場動態和客戶購買行為。

FPNV定位矩陣

FPNV定位矩陣對於評估Duchenne氏肌肉失養症藥物市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對Duchenne氏肌肉失養症治療藥物市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，以獲得市場競爭優勢。

本報告對以下幾個方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.Duchenne氏肌肉失養症治療藥物市場規模及預測是多少？

2.Duchenne氏肌肉失養症治療藥物市場預測期內需要考慮投資的產品、細分市場、應用和領域有哪些？

3.Duchenne氏肌肉失養症治療藥物市場的技術趨勢和法規結構是什麼？

4.Duchenne氏肌肉失養症治療藥物市場主要供應商的市場佔有率是多少？

5. 進入Duchenne氏肌肉失養症藥物市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 包括Duchenne氏肌肉失養症在內的遺傳性疾病盛行率增加
      • 遺傳學研究的持續進展以及 DMD 遺傳基礎的突破
    • 抑制因素
      • DMD藥物治療高成本
    • 機會
      • CRISPR/Cas9等基因編輯工具與技術的進步
      • 開發適合個人遺傳特徵的個人化醫療方法
    • 任務
      • DMD 藥物認知度低和副作用
  • 市場區隔分析
    • 藥物類型：Casimersen 作為Duchenne氏肌肉失養症的標靶治療藥物越來越受歡迎
    • 最終用途：門診中心更多採用 DMD 藥物
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章Duchenne氏肌肉失養症治療藥物市場（依藥物類型）

  • 克什默森
  • 德弗拉札外套
  • 德萊恩肌肉營養不良劑莫克斯帕沃韋克
  • 埃特普里森
  • 戈羅迪爾森
  • 維爾特拉爾森

第7章Duchenne氏肌肉失養症治療藥物市場（依管理方式）

  • 口服
  • 監護人

第8章Duchenne氏肌肉失養症治療藥物市場：依最終用途分類

  • 門診中心
  • 家庭護理設置
  • 醫院/診所

第9章北美和南美Duchenne氏肌肉失養症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區Duchenne氏肌肉失養症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲Duchenne氏肌肉失養症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Agamly 獲得 FDA核准作為第一個用於治療Duchenne氏肌肉失養症的“解離類固醇發炎藥”
    • FDA核准新的類固醇發炎藥物治療Duchenne氏肌肉失養症
    • FDA核准首個基因療法治療選定的Duchenne氏肌肉失養症患者
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-5E3B35529469

[182 Pages Report] The Duchenne Muscular Dystrophy Drugs Market size was estimated at USD 1.57 billion in 2023 and expected to reach USD 1.70 billion in 2024, at a CAGR 8.61% to reach USD 2.80 billion by 2030.

The Duchenne muscular dystrophy (DMD) drugs market focuses on the sales, development, and production of pharmaceuticals specifically aimed at treating DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. Advancements in genetic research and breakthroughs in understanding the genetic basis of DMD are leading to more targeted and effective treatments, contributing to the market expansion. Higher global healthcare expenditure enables better treatment access for DMD, contributing to market growth. Funding and initiatives by governments and non-profit organizations boost research and development efforts, enhancing the market adoption of DMD drugs. Stringent regulatory requirements for drug approval and market introduction may delay access to innovative treatments, posing challenges in the market space. Moreover, ongoing advancements in gene editing technologies such as CRISPR/Cas9 and other gene-editing tools offer potential for curative treatments of Duchenne muscular dystrophy. The development of personalized medicine approaches tailored to individual genetic profiles may improve efficacy and minimize side effects, generating opportunities for market growth.

KEY MARKET STATISTICS
Base Year [2023] USD 1.57 billion
Estimated Year [2024] USD 1.70 billion
Forecast Year [2030] USD 2.80 billion
CAGR (%) 8.61%

Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy

Casimersen is approved for treating DMD in patients with a confirmed mutation due to exon 45 skipping. This need-based preference for casimersen is critical for patients with a specific genetic makeup, providing a targeted treatment option. Deflazacort ensures efficacy in delaying disease progression and improving muscle strength to slow the progression of DMD across a broad range of patients, regardless of their specific genetic mutation. Delandistrogene Moxeparvovec (Roctavian) gene therapy is designed for patients that benefit from a direct approach to correcting the gene defect responsible for DMD. Eteplirsen (Exondys 51) is preferred for DMD patients observing confirmed mutation of the DMD gene due to exon 51 skipping. Golodirsen meets the needs of a niche patient group, offering a targeted genetic treatment with a specific genetic mutation amenable to exon 53 skipping. Viltolarsen is approved for DMD patients amenable to exon 53 skipping that targets a specific genetic alteration, providing a precision medicine approach for affected patients.

End-Use: Increasing adoption of DMD drugs in ambulatory centers

Ambulatory centers, also known as outpatient care centers, provide medical services to patients that do not require hospital admission. Ambulatory center facilities have been increasingly preferred for routine check-ups, diagnosis, and the management of chronic conditions such as DMD due to their convenience and cost-effectiveness. Homecare settings represent a rapidly growing segment that caters to the preference for receiving healthcare services, including DMD drug treatments, in the patient's home. Homecare settings allow for continuous, personalized care and the administration of DMD medications in the comfort of the patient's home.

Regional Insights

In the Americas region, the United States and Canada are pivotal due to the strong presence of key players engaged in developing Duchenne Muscular Dystrophy (DMD) drugs. The Americas region is characterized by high consumer awareness, substantial investments in R&D, and favorable government policies. The United States holds a key position in developing breakthrough therapies and has several patents filed for innovative DMD treatments. Canada demonstrates strong governmental support and public-private partnerships, fostering growth in the market arena. The European Union countries are at the forefront regarding regulatory support for DMD drug development and have several initiatives supporting research and access to treatment. Patent activity is high in the EMEA region, with several countries contributing to discoveries. The Middle East region, although smaller in terms of market size, is witnessing increased investment and growing awareness. Africa faces challenges related to healthcare infrastructure and treatment access and shows potential for growth through international partnerships and investments. The Asia Pacific region, especially China, Japan, and India, has grown significantly in the DMD drugs market. The market growth in the APAC countries is attributed to increasing awareness, governmental initiatives, and improving healthcare infrastructure. Research and investment in APAC countries have been robust, with Japan leading in innovative therapies and patent filings. China and India are rapidly advancing in research and offering cost-effective treatments, significantly affecting market dynamics and customer purchasing behaviors.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Duchenne Muscular Dystrophy Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Duchenne Muscular Dystrophy Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Duchenne Muscular Dystrophy Drugs Market, highlighting leading vendors and their innovative profiles. These include Anuh Pharma Limited, Arlak Biotech Pvt.Ltd., Aurigene Pharmaceutical Services Ltd., Bayer Pharmaceutical, Cipla Inc., Enomark, Glasier Wellness, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Leo Pharma, Lifecare Neuro Products Limited, Mankind Pharma Ltd., Merck & Co., Inc.,, MODASA Pharmaceuticals Pvt. Ltd., Novartis AG, Pfizer Inc., QndQ Derma, RayBiotech, Inc., Ronyd Healthcare Pvt Ltd., Sarepta Therapeutics, Inc., Sumitomo Corporation, Texas Pharmaceuticals Pvt. Ltd., Wallace Pharmaceuticals Pvt Ltd., Wellona Pharma, and Zuventus Healthcare Ltd..

Market Segmentation & Coverage

This research report categorizes the Duchenne Muscular Dystrophy Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Type
    • Casimersen
    • Deflazacort
    • Delandistrogene Moxeparvovec
    • Eteplirsen
    • Golodirsen
    • Viltolarsen
  • Administration Method
    • Oral
    • Parental
  • End-Use
    • Ambulatory Centres
    • Homecare Settings
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Duchenne Muscular Dystrophy Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Duchenne Muscular Dystrophy Drugs Market?

3. What are the technology trends and regulatory frameworks in the Duchenne Muscular Dystrophy Drugs Market?

4. What is the market share of the leading vendors in the Duchenne Muscular Dystrophy Drugs Market?

5. Which modes and strategic moves are suitable for entering the Duchenne Muscular Dystrophy Drugs Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic diseases including Duchenne muscular dystrophy
      • 5.1.1.2. Ongoing advancements in genetic research and breakthroughs in understanding the genetic basis of DMD
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of DMD drug therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene-editing tools and gene editing technologies such as CRISPR/Cas9
      • 5.1.3.2. Development of personalized medicine approaches tailored to individual genetic profiles
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and side affects associated with DMD drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Rising preference for casimersen for targeted treatment of Duchenne muscular dystrophy
    • 5.2.2. End-Use: Increasing adoption of DMD drugs in ambulatory centers
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Duchenne Muscular Dystrophy Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Casimersen
  • 6.3. Deflazacort
  • 6.4. Delandistrogene Moxeparvovec
  • 6.5. Eteplirsen
  • 6.6. Golodirsen
  • 6.7. Viltolarsen

7. Duchenne Muscular Dystrophy Drugs Market, by Administration Method

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Duchenne Muscular Dystrophy Drugs Market, by End-Use

  • 8.1. Introduction
  • 8.2. Ambulatory Centres
  • 8.3. Homecare Settings
  • 8.4. Hospitals & Clinics

9. Americas Duchenne Muscular Dystrophy Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Duchenne Muscular Dystrophy Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Agamree Receives FDA Approval as First "Dissociative Steroidal Anti-Inflammatory" to Treat Duchenne Muscular Dystrophy
    • 12.3.2. FDA Approves a New Steroidal-Type Anti-Inflammatory Drug for Duchenne Muscular Dystrophy
    • 12.3.3. FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET DYNAMICS
  • FIGURE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY CASIMERSEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DEFLAZACORT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DELANDISTROGENE MOXEPARVOVEC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ETEPLIRSEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY GOLODIRSEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY VILTOLARSEN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY PARENTAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY AMBULATORY CENTRES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY DRUG TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY ADMINISTRATION METHOD, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 289. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023